Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

Fibroblast growth factor receptor 4 (FGFR4) is thought to be a driver in several cancer types, most notably in hepatocellular carcinoma. One way to achieve high potency and isoform selectivity for FGFR4 is covalently targeting a rare cysteine (C552) in the hinge region of its kinase domain that is not present in other FGFR family members (FGFR1-3). Typically, this cysteine is addressed via classical acrylamide electrophiles. We demonstrate that noncanonical covalent "warheads" based on nucleophilic aromatic substitution (SNAr) chemistry can be employed in a rational manner to generate highly potent and (isoform-)selective FGFR4 inhibitors with a low intrinsic reactivity. Key compounds showed low to subnanomolar potency, efficient covalent inactivation kinetics, and excellent selectivity against the other FGFRs, the kinases with an equivalent cysteine, and a representative subset of the kinome. Moreover, these compounds achieved nanomolar potencies in cellular assays and demonstrated good microsomal stability, highlighting the potential of SNAr-based approaches in covalent inhibitor design.

• Publication year

  2024

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2024-04-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.3c02483PMID 38604131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.

  2024cited by this paper
• Covalent chemical probes for protein kinases

  2023cited by this paper
• Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.

  2023cited by this paper
• A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma

  2023cited by this paper
• Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes

  2023cited by this paper
• An update on the discovery and development of reversible covalent inhibitors

  2023cited by this paper
• Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.

  2023cited by this paper
• Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.

  2022cited by this paper
• Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected?

  2022cited by this paper
• The Ascension of Targeted Covalent Inhibitors.

  2022cited by this paper
• Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

  2022cited by this paper
• Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα

  2022cited by this paper
• Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

  2022cited by this paper
• Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.

  2022cited by this paper
• Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.

  2022cited by this paper
• Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors

  2022cited by this paper
• Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors.

  2022cited by this paper
• Discovery of CC-99677, a Selective Targeted Covalent MAPKAPK2 (MK2) Inhibitor for Autoimmune Disorders.

  2022cited by this paper
• A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins

  2022cited by this paper
• Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma.

  2022cited by this paper
• Never Gonna Give You Up - Current Developments in Covalent Protein Kinase Inhibitors.

  2022cited by this paper
• Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

  2021cited by this paper
• Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.

  2021cited by this paper
• Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)

  2021cited by this paper
• Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.

  2021cited by this paper
• Chemical Probes for Understudied Kinases: Challenges and Opportunities.

  2021cited by this paper
• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

  2021cited by this paper
• Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

  2021cited by this paper
• FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice

  2021cited by this paper
• Tetramethylammonium Fluoride Alcohol Adducts for SNAr Fluorination.

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

  2020cited by this paper
• Insight Into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib Through Enzyme Kinetic Studies.

  2020cited by this paper
• Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

  2019cited by this paper
• First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

  2019cited by this paper
• The Cysteinome of Protein Kinases as a Target in Drug Development.

  2018cited by this paper
• 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

  2018cited by this paper
• Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors

  2018cited by this paper
• Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.

  2018cited by this paper
• Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.

  2017cited by this paper
• Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

  2017cited by this paper
• Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

  2017cited by this paper
• H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.

  2017cited by this paper
• Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.

  2017cited by this paper
• Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

  2016cited by this paper
• Kinase hinge binding scaffolds and their hydrogen bond patterns.

  2015cited by this paper
• First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

  2015cited by this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014cited by this paper
• Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models

  2014cited by this paper
• Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

  2014cited by this paper
• Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

  2013cited by this paper
• Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

  2013cited by this paper
• Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

  2013cited by this paper
• Irreversible protein kinase inhibitors: balancing the benefits and risks.

  2012cited by this paper
• Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma

  2012cited by this paper
• Design and Preparation of New Palladium Precatalysts for C-C and C-N Cross-Coupling Reactions.

  2012cited by this paper
• FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone

  2011cited by this paper
• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

  2011cited by this paper
• The resurgence of covalent drugs

  2011cited by this paper
• Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.

  2011cited by this paper
• Recognition-domain focused chemosensors: versatile and efficient reporters of protein kinase activity.

  2008cited by this paper
• Cellular signaling by fibroblast growth factor receptors.

  2005cited by this paper
• Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.

  2004cited by this paper
• Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics.

  2003cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• trans-1,2-Diaminocyclohexane Derivatives as Chiral Reagents, Scaffolds, and Ligands for Catalysis: Applications in Asymmetric Synthesis and Molecular Recognition.

  1997cited by this paper
• Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters

  1995cited by this paper

• Modular Vinyl Phosphonamidates for Cysteine-Directed Protein Targeting.

  2026cites this paper
• Go for Gold: Development of a Scalable Synthesis of [1‐(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors

  2025cites this paper
• Enhancing Selectivity and Potency of SNAr Covalent Inhibitors of NADPH Oxidase Enzymes.

  2025cites this paper
• Warhead Strategy for Targeted Protein S-Nitrosation.

  2025cites this paper
• High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024.

  2025cites this paper
• Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives.

  2025cites this paper
• Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma

  2025cites this paper
• Development of a series of novel potent and selective irreversible covalent FGFR4 inhibitors with a mix-and-match strategy.

  2025cites this paper
• Single-plate kinome screening in live-cells to enable highly cost-efficient kinase inhibitor profiling.

  2025cites this paper
• Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP

  2025cites this paper
• A “Ligand First” Approach toward Selective, Covalent JNK2/3 Inhibitors

  2025cites this paper
• Demystifying Functional Parameters for Irreversible Enzyme Inhibitors.

  2024cites this paper
• Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story

  2024cites this paper
• Probing the Protein Kinases' Cysteinome by Covalent Fragments.

  2024cites this paper
• Innovative design and potential applications of covalent strategy in drug discovery.

  2024cites this paper
• Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.

  2024cites this paper
• PTX promotes breast cancer migration and invasion by recruiting ATF4 to upregulate FGF19.

  2024cites this paper